Skip to main content
. Author manuscript; available in PMC: 2018 Jan 6.
Published in final edited form as: J Proteome Res. 2016 Oct 20;16(1):355–365. doi: 10.1021/acs.jproteome.6b00617

Figure 5.

Figure 5

RA patients have T cells recognizing GrB-exposed PAD4 peptides. (A) PBMCs from DR1 and/or DR4 positive patients with RA (n = 19) or non-RA disease and healthy controls (n = 6 scleroderma patients, n = 2 psoriatic arthritis patients, and n = 2 healthy controls) were stimulated with peptides identified by the cell-free antigen processing system or CEFT (a pool of peptides from infectious antigens). The % CD154+CD4+ T cells for each patient following incubation with the peptides over background stimulation to the negative control POLR3 peptide is shown. Dotted lines indicate 1 standard deviation (0.08), 2 standard deviations (0.13), and 3 standard deviations (0.18) above the mean of the non-RA controls. (B) RA patients are grouped according to the presence of DR4 (B) or DR1 and DR4 (C) alleles, and T cell responses to PAD4 peptides over the negative control are shown. Data were analyzed using a Wilcoxon rank-sum (Mann–Whitney) test and the median, IQR, and p-values are shown; p < 0.05 was considered significant.